Treatment of Hyperoxia-Induced Lung Injury with Lung Mesenchymal Stem Cells in Mice.

Yabo Mei,Wanqiao Zhang,Hui Dong,Yan Wang,Chong Chen,Zhichun Feng,Ming Chi

doi:10.1155/2018/5976519

Abstract

Objective Bronchopulmonary dysplasia (BPD) is a common chronic lung disease in preterm neonates and has no effective treatment. This study aimed to investigate the therapeutic effects of neonatal mouse lung resident mesenchymal stem cells (L-MSCs) on the hyperoxia-induced lung injury. Methods L-MSCs were separated and identified according to the MSC criterions. Hyperoxia-Induced Lung Injury (HILI) of neonatal KM mice was induced with hyperoxia (FiO2 = 60%) and investigated with pathological methods. Neonatal KM mice were divided into 3 groups (hyperoxia + L-MSC group, hyperoxia + PBS group, and air control group). Mice in the hyperoxia + L-MSC group were treated with L-MSCs at 3, 7, and 14 days after birth. After hyperoxia exposure for 21 days, the lung pathology, Radial Alveolar Count (RAC), CD31 expression, and vascular endothelial growth factor (VEGF) expression were investigated. Results After hyperoxia exposure, the body weight, RAC, CD31 expression, and VEGF expression in the hyperoxia + L-MSC group were significantly better than those in the hyperoxia + PBS group but inferior to those in the air control group significantly. These indicate L-MSCs are partially protective on the lung injury of mice with hyperoxia-induced BPD. Conclusion L-MSCs are helpful for the prevention and treatment of BPD, and endogenous L-MSCs may play a role in the postinjury repair of the lung.

Highlights

Bronchopulmonary dysplasia (BPD) is a specific chronic respiratory disease in neonates and refers to the developmental arrest of the immature lungs due to some pathological factors
The optical density of CD31 expression analysis confirmed the proangiogenic effect of lung resident mesenchymal stem cells (L-mesenchymal stem cells (MSCs)) under hyperoxia exposure
BPD is a common complication in preterm neonates, especially the very low birth weight infants and clinically characterized by oxygen dependence

Summary

Introduction

Bronchopulmonary dysplasia (BPD) is a specific chronic respiratory disease in neonates and refers to the developmental arrest of the immature lungs due to some pathological factors. Cellular therapies using exogenously mesenchymal stem cells (MSCs), as alternative therapies, may represent the breakthrough therapies for the treatment of BPD and have attracted growing attention in the past decade [3]. The improvement in lung function and architecture had been verified in a growing body of animal models received exogenously MSCs or MSC-conditioned media [4,5,6], but very little is known about that of lungs’ own endogenous MSCs [4, 5, 7]. As lung-resident MSCs, L-MSCs producing specific basement membrane and promoting epithelial progenitor cells’

Methods

Results

Conclusion